CN110357843A - 一种新型桑黄素及其提取方法与应用 - Google Patents
一种新型桑黄素及其提取方法与应用 Download PDFInfo
- Publication number
- CN110357843A CN110357843A CN201910647515.3A CN201910647515A CN110357843A CN 110357843 A CN110357843 A CN 110357843A CN 201910647515 A CN201910647515 A CN 201910647515A CN 110357843 A CN110357843 A CN 110357843A
- Authority
- CN
- China
- Prior art keywords
- morin
- methanol
- extracting method
- phellinus
- fermented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 235000007708 morin Nutrition 0.000 title claims abstract description 38
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims abstract description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 72
- 239000007788 liquid Substances 0.000 claims abstract description 26
- 238000000855 fermentation Methods 0.000 claims abstract description 23
- 230000004151 fermentation Effects 0.000 claims abstract description 23
- 241000123107 Phellinus Species 0.000 claims abstract description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000000126 substance Substances 0.000 claims abstract description 11
- 239000007791 liquid phase Substances 0.000 claims abstract description 7
- 239000001963 growth medium Substances 0.000 claims abstract description 5
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000012071 phase Substances 0.000 claims description 6
- 230000003064 anti-oxidating effect Effects 0.000 claims description 5
- 239000002054 inoculum Substances 0.000 claims description 5
- 239000002609 medium Substances 0.000 claims description 5
- 230000003519 ventilatory effect Effects 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 4
- 239000008188 pellet Substances 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 229940123457 Free radical scavenger Drugs 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- 239000002516 radical scavenger Substances 0.000 claims description 2
- 150000003254 radicals Chemical class 0.000 abstract description 14
- 150000001875 compounds Chemical class 0.000 abstract description 12
- 239000003963 antioxidant agent Substances 0.000 abstract description 7
- 230000003078 antioxidant effect Effects 0.000 abstract description 7
- 235000006708 antioxidants Nutrition 0.000 abstract description 7
- -1 styrylpyrone class compound Chemical class 0.000 abstract description 6
- 238000005481 NMR spectroscopy Methods 0.000 abstract description 4
- 238000001819 mass spectrum Methods 0.000 abstract description 4
- 238000002211 ultraviolet spectrum Methods 0.000 abstract description 4
- SGJNQVTUYXCBKH-HNQUOIGGSA-N hispidin Chemical compound O1C(=O)C=C(O)C=C1\C=C\C1=CC=C(O)C(O)=C1 SGJNQVTUYXCBKH-HNQUOIGGSA-N 0.000 abstract description 3
- SGJNQVTUYXCBKH-UHFFFAOYSA-N hispidin Natural products O1C(=O)C=C(O)C=C1C=CC1=CC=C(O)C(O)=C1 SGJNQVTUYXCBKH-UHFFFAOYSA-N 0.000 abstract description 3
- 239000000178 monomer Substances 0.000 abstract description 3
- 238000004566 IR spectroscopy Methods 0.000 abstract description 2
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 2
- 239000000049 pigment Substances 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 15
- 238000001228 spectrum Methods 0.000 description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 13
- 239000000523 sample Substances 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 8
- 230000007760 free radical scavenging Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000010183 spectrum analysis Methods 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 6
- 229930003268 Vitamin C Natural products 0.000 description 6
- 235000019154 vitamin C Nutrition 0.000 description 6
- 239000011718 vitamin C Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 5
- 230000002000 scavenging effect Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 241001311294 Iochroma baumii Species 0.000 description 3
- 240000000249 Morus alba Species 0.000 description 3
- 235000008708 Morus alba Nutrition 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 3
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000005311 nuclear magnetism Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 241000222382 Agaricomycotina Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000221198 Basidiomycota Species 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241000222341 Polyporaceae Species 0.000 description 2
- 241000222383 Polyporales Species 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229910002567 K2S2O8 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 244000018795 Prunus mume Species 0.000 description 1
- 235000011158 Prunus mume Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003026 anti-oxygenic effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 150000001555 benzenes Chemical group 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- AQOVEYNSQFBSQX-UHFFFAOYSA-N morinin C Natural products COC1=CC=C(C=CCOC(=O)C(CO)=CC)C=C1OC AQOVEYNSQFBSQX-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
- C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/162—Heterorings having oxygen atoms as the only ring heteroatoms, e.g. Lasalocid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了新型桑黄素及其提取方法与应用,提取方法包括:将桑黄采用PDA培养基进行发酵培养,发酵培养液用乙酸乙酯进行萃取,萃取物浓缩得浸膏,浸膏溶于甲醇后,采用高效液相对其进行分离纯化,制得。本发明从桑黄发酵液中成功分离出了纯度达到98.35%的主产物,利用紫外光谱、红外光谱、质谱和核磁共振波谱仪确定该化合物为两个hispidin单体在C‑3聚合而成的苯乙烯吡喃酮类化合物,该类化合物可以作为一种天然的色素,具有很好的抗氧化,清除自由基,抗肿瘤和降血糖作用。
Description
技术领域
本发明属于食药用菌活性成分提取技术领域,具体涉及一种新型桑黄素及其提取方法与应用。
背景技术
桑黄又名桑耳、胡孙眼、梅树菌,是一种名贵的多年生大型食药用菌,属担子菌亚门(Basidiomycota)、层菌纲(Hymenomycetes)、多孔菌目(Polyporales)、多孔菌科(Polyporaceae)、针层孔菌属(Phelliunus),它主要寄生于桑树、桦树、杨树等阔叶树的树干上,有“森林黄金”的美称。据目前研究表明,桑黄中所含有各种化学物质不下百种,并且这些化学物质大多数都有药理活性,能够治疗多种疾病,有良好的应用和开发前景。以往的研究都集中在桑黄子实体或发酵菌丝体中所含化学成分的分析分离方面,而发酵液中化学成分的分析及分离目前还属于空白。
发明内容
针对现有技术中的上述不足,本发明提供了一种新型桑黄素及其提取方法与应用,首次从桑黄中提取出了一种新化合物,该物质具有良好的抗氧化能力和清除自由基的能力,具有很好的应用价值。
为实现上述目的,本发明解决其技术问题所采用的技术方案是:
一种新型桑黄素,其分子式为C26H19O10,化学式如下所示:
上述桑黄素是从桑黄发酵培养液中分离得到的。
进一步地,桑黄素的提取方法,包括以下步骤:
将桑黄采用PDA培养基进行发酵培养,发酵结束后,过滤,得发酵培养液,发酵培养液用乙酸乙酯进行萃取,萃取物浓缩得浸膏,浸膏溶于甲醇后,采用高效液相对其进行分离纯化;其中,高效液相色谱条件:流动相A为水,流动相B为甲醇,梯度洗脱程序为0-5min为30%-40%的甲醇水溶液,5-55min为 40%-70%的甲醇水溶液,室温,流速为3mL/min,检测波长280nm,收集 27-28.5min的洗脱组分,然后浓缩除去甲醇,得到桑黄素。
进一步地,对桑黄进行发酵培养的具体过程为:将桑黄接种到PDA固体培养基中进行活化,然后再将活化后的桑黄接种到PDA液体培养基中进行培养,得种子液,将种子液中的菌丝球打碎后接种到发酵罐中,接种量为8-12%(体积百分数),在26-28℃,160-180r/min,通气量为0.5-0.8vvm条件下进行发酵培养 6-8天;优选为发酵培养时接种量为10%,发酵温度为28℃,转速为180r/min,通气量为0.6vvm,发酵培养时间为8天。
进一步地,浸膏溶于甲醇,浓度为18-22mg/mL,优选为20mg/mL。
上述桑黄素可用于制备抗氧化药物、制备自由基清除剂、抗肿瘤药物或降血糖药物。
本发明提供的新型桑黄素及其提取方法与应用,具有以下有益效果:
本发明从桑黄发酵液中成功分离出了纯度达到98.35%的主产物,利用紫外光谱、红外光谱、质谱和核磁共振波谱仪确定该化合物为两个hispidin单体在 C-3聚合而成的苯乙烯吡喃酮类化合物,该类化合物可以作为一种天然的色素,有很好的抗氧化,清除自由基,抗肿瘤和降血糖作用。
附图说明
图1为实施例1所得产物的紫外光谱分析结果图。
图2为实施例1所得产物的傅里叶红外光谱分析结果图。
图3为实施例1所得产物的质谱分析结果图。
图4为实施例1所得产物的1H核磁图谱。
图5为实施例1所得产物的13C核磁图谱。
图6为实施例1所得产物的HMQC核磁图谱。
图7为实施例1所得产物的1H-1HCOSY核磁图谱。
图8为实施例1所得产物的HMBC核磁图谱。
具体实施方式
实施例1
1、培养基配置
PDA固体培养基:取200g削皮土豆切成0.5cm的正方体小块,加水煮沸约20min,八层纱布过滤,加入20g琼脂继续加热,待琼脂完全溶解后加入20g葡萄糖,搅拌均匀,补水到1L。分装到试管和锥形瓶,115℃灭菌20min,冷却后备用。
PDA液体培养基:操作如上,不加琼脂。
2、桑黄(I.baumii)发酵培养
桑黄(Innotous baumii)ATCC36121购于中国农业科学研究院菌种保藏中心。
种子液制备:取生长良好的I.baumii平板,用灭菌后的打孔器,打取直径为0.5cm生长一致的菌饼5块,加入到含有100mL PDA液体的250mL三角瓶中,恒温28℃,转速180r/min,培养7天,然后用高速匀浆机将菌丝球打碎,制得种子液。
发酵培养方法:将种子液接种到发酵罐中,发酵罐装液量为4.5L,接种量为10%,温度28℃,转速180r/min,通气量为0.6vvm,培养到第8天后结束发酵。
3、制备桑黄(I.baumii)发酵液浸膏
将发酵液经过滤纸过滤,除去菌丝球,得滤液发酵液,滤液发酵液透过10μm 聚丙烯滤膜,进一步除杂,重复2次。然后将收集的发酵液滤液用等量的乙酸乙酯萃取三次,收集萃取的乙酸乙酯,低温旋转蒸发仪将乙酸乙酯除去,得到发酵液浓缩样品。
将发酵液浓缩样溶于乙醇中,观察其颜色为柠檬黄色,取少量液体滴于滤纸片上,置于紫外检测器上观察其荧光颜色,荧光颜色为黄绿色。
4、分离纯化
将发酵液浸膏溶于甲醇使其浓度为20mg/mL,采用高效液相对其进行分离纯化;其中,高效液相色谱条件:流动相A为水,流动相B为甲醇,梯度洗脱程序为0-5min为30%-40%的甲醇水溶液,5-55min为40%-70%的甲醇水溶液,室温,流速为3mL/min,检测波长280nm,收集27-28.5min的洗脱组分,然后浓缩除去甲醇,得到桑黄素,纯度为98.35%。
对上述制得的产物进行如下检测分析:
1、紫外光谱分析
取纯化后的产物溶解在甲醇溶液中并稀释到合适的倍数,利用紫外光谱仪对其进行光谱扫描,使用紫外光谱对样品从200-800nm进行检测,紫外光谱分析结果如图1所示,由图1可知,在376nm、253nm、220nm处有较强的吸收,在376nm处为较大的共轭体系吸收,并且还可能含有助色基团,在253nm处为苯环的吸收,在220nm处为共轭双键体系形成的K吸收带,说明该化合物中含有苯环和较多双键。
2、傅里叶红外光谱分析
取纯化后的产物溶解在甲醇溶液中,滴一滴在压好的KBr片上,然后在高热灯下烘干完全除去其甲醇,进行红外检测,扫面波长为400-4000cm-1,扫描 64次。傅里叶红外光谱分析结果如图2所示,由图2可知,3427cm-1为酚羟基伸缩震动吸收峰,2901cm-1和2831cm-1为苯环亚甲基反对称伸缩震动和对称伸缩震动吸收峰,1630cm-1为醛基特征吸收峰,1400cm-1为-CH面内弯曲震动吸收峰,1071cm-1为酯基吸收峰,968cm-1反式二氢弯曲震动吸收峰。
3、质谱分析
取纯化后的产物溶解在甲醇溶液中并稀释到合适的倍数,对其作质谱分析。质谱条件为,ESI(+)离子源,脱溶剂温度350℃,喷雾电压3.0kV,锥孔电压是 50V,氮气流量是350mL/h。阳离子质谱图如图3所示,由图3可知,基峰m/z 491 处给出[M+H]+,在m/z 513处给出[M+Na]+,由此可以推断,该化合物的相对分子质量为490。
4、核磁共振波谱分析
取纯化后的产物10mg放入真空干燥箱中过夜,让其充分干燥,然后分别复溶于氘代甲醇和氘代二甲基亚砜溶液中(核磁实验第一次采用氘代甲醇试剂,第二次采用氘代二甲基亚砜,通过对比2次图谱的核磁结果,可以排除以氘代甲醇为溶剂的氢谱3.74、1.99处和碳谱25.09处为溶剂所带杂质的干扰),加入核磁管,用核磁共振波谱进行扫描,测量其1H(氢谱)、13C(碳谱)以及HMQC (碳氢直接相关)、HMBC(碳氢远程相关)、1H-1H COSY(相邻氢原子识别),根据核磁图谱解析其化学结构。
目标产物的核磁共振波谱分析数据如表1所示,化合物碳原子编号见分子式:
表1核磁共振波谱数据
图4为1H核磁图谱,图5为13C核磁图谱,图6为HMQC核磁图谱,图7 为1H-1HCOSY核磁图谱,图8为HMBC核磁图谱。
由图4中可知,该化合物有6种不同类型的氢原子,在6.67(1H,d,16Hz) 和7.05(1H,d,16Hz)信号处有典型的反式取代的双键,在6.94(1H,dd,2Hz; 8Hz),6.77(1H,d,8Hz)和7.32(1H,s)质子信号则证明存在1,3,4-三取代的苯环质子,根据紫外光谱信息和定性分析结果,该三取代苯环自旋系统的两个取代基为邻位的羟基,另一个位置上为烯烃取代。
由图5和图6可知,该化合物总共有13种碳原子,在100.3、113.41、115.15、115.45、120.56、135.93显示6个SP2杂化的亚甲基,在166.33、67.47、171.99、 160.67、127.40、145.38、147.28显示为季碳。
由图7可知,H-7和H-8相关,结构为-CH=CH-,H-13和H-14相关,为苯环上的-CH=CH-结构。
由图8可知,H-13与C-11、C-12、C-14有关,H-14与C-11、C-12、C-8、 C14有关,H10和C-12、C-11、C-14、C-8相关,可以断定C-9、C-10、C-11、 C-12、C-13、C-14连接为一个苯环,且C-9位连接了C-8的烯烃。H-7与C-6、 C-8、C-9、C-5相关,H-8与C-9、C-10、C-6,C-14有关,根据这些远程相关建立以上片段结构之间以及他们与C-3、C-4之间的连接。化合物的不饱和度为 7,分子中存在5个连氧的SP2杂化季碳原子,判断其结构中存在一个内酯环, C-2和C-6的化学位移值确定它们之间以内酯连接。另外在C-2和C-3与任何质子都没有相关,根据季碳C-3在高场化学位移为(δ67.47),判断C-2与C-3相连,不过该化合物C-3处应该再连接一个hispidin单体形成二聚体,该化合物为一个新的化合物,命名为桑黄素,化学结构如下所示。
5、抗氧化性能
(1)总抗氧化性能测试
实验操作参考南京建成生物公司研究所的总抗氧化能力(T-AOC)试剂盒,测定桑黄素的总抗氧化能力,以维生素C为阳性对照。定义在37℃时,每分钟每毫升使反应体系的吸光度每增加0.01时,为一个总抗氧化能力单位,按如下公式计算总抗氧化能力,其结果见表2。
其中,N为稀释倍数。
表2桑黄素总抗氧化能力
由表2可知,在高浓度816μM下,桑黄素的总抗氧化性能比维生素C高 6.48U/mL,为23.99U/mL。但当浓度低于51μM,桑黄素和维生素C的总抗氧化性能则没有明显的差距。
(2)DPPH-自由基清除能力
分别配置816μM的桑黄素和维生素C原液,使用时分别稀释2倍、4倍、8 倍、16倍、32倍、64倍、128倍。取100μM DPPH溶液100μL加入到100μL 不同浓度的桑黄素和维生素C溶液中,混匀,以样品液为空白对照。25℃反应 20min,酶标仪517nm测量吸光度,样品液吸光度为A1,空白对照吸光度为A0,不加样吸光度为A。按如下公式计算DPPH-清除率,其结果见表3。
(3)羟基自由基清除能力
分别取50μL 9mM FeSO4、9mM水杨酸和不同浓度的样品液混匀,再加入 50μL8.8mM的H2O2,混匀,以FeSO4水杨酸、H2O2为空白对照,37℃反应30min,酶标仪510nm测量吸光度,样品液吸光度为A1,空白对照吸光度为A0,不加样吸光度为A。按如下公式计算羟基自由基的清除率,其结果见表3。
(4)超氧基自由基清除能力
取2950μL pH为7.4的Tris-HCl缓冲液加到比色皿中,再加50μL的60mM 的连苯三酚,迅速混匀,每30s读数一次,至360s时为止,ΔA=A325nm,30s-A325nm,360s。取200μL样品液加入比色皿,再加入2750μL Tris-HCl缓冲液,再加50μL的连苯三酚,迅速混匀每30s读数一次,至360s时为止。此时ΔA样=A325nm,30s-A325nm,360s。按如下公式计算超氧基自由基清除能力的清除率,其结果见表3。
(5)ABTS+自由基清除能力
取2mL 7.4mM ABTS与2mL K2S2O8混匀,室温避光反应12h,然后用乙醇稀释到OD734nm为0.3左右。取稀释的混合液800μL,加入200μL不同浓度的样品液混匀,室温静置6min,酶标仪在测734nm的吸光度为A1。空白对照样品液为A0,A为不加样品液的吸光度。按如下公式计算ABTS+自由基清除能力,其结果见表3。
表3桑黄素自由基清除能力
由表3可知,桑黄素对这四种自由基都具有一定的清除能力。通常情况下,桑黄素对DPPH-、O2 -、ABTS+自由基的清除能力弱于维生素C,但是在浓度低于204μM下,桑黄素清除O2 -自由基的能力确反而比维生素C高,而且清除率稳定在30%左右。桑黄素在浓度为816μM对OH-自由基的清除能力比维生素C 高30.45%,为85.1%。桑黄素对DPPH-、OH-、O2 -、ABTS+、O2 -自由基抑制率的IC50分别为18.62μM、222.56μM、611.41μM、73.33μM。
机体自由基的产生是引起癌症、衰老、心血管疾病等退变性疾病的根源,生物体内常见的自由基主要是OH-、O2 -、烷氧基自由基等,其中O2 -产生最早, OH-自由基的损害能力最强。桑黄素对OH-自由基的清除能力比较强,并且在低浓度时对O2 -自由基的清除能力比较稳定。如果通过机体摄入桑黄素,能够有效的阻断自由基的形成,从根本上防止体内形成过多的自由基,从而达到预防癌症、衰老、心血管疾病等的作用。
Claims (10)
1.一种新型桑黄素,其特征在于,分子式为C26H19O10,化学结构式如下所示:
2.权利要求1所述的桑黄素的提取方法,其特征在于,所述的桑黄素是从桑黄发酵培养液中分离得到的。
3.根据权利要求2所述的桑黄素的提取方法,其特征在于,包括以下步骤:
将桑黄采用PDA培养基进行发酵培养,发酵结束后,过滤,得发酵培养液,发酵培养液用乙酸乙酯进行萃取,萃取物浓缩得浸膏,浸膏溶于甲醇后,采用高效液相对其进行分离纯化;其中,高效液相色谱条件:流动相A为水,流动相B为甲醇,梯度洗脱程序为0-5min为30%-40%的甲醇水溶液,5-55min为40%-70%的甲醇水溶液,室温,流速为3mL/min,检测波长280nm,收集27-28.5min的洗脱组分,然后浓缩除去甲醇,得到桑黄素。
4.根据权利要求3所述的桑黄素的提取方法,其特征在于,对桑黄进行发酵培养的具体过程为:将桑黄接种到PDA固体培养基中进行活化,然后再将活化后的桑黄接种到PDA液体培养基中进行培养,得种子液,将种子液中的菌丝球打碎后接种到发酵罐中,按体积百分数计,接种量为8-12%,在26-28℃,160-180r/min,通气量为0.5-0.8vvm条件下进行发酵培养6-8天。
5.根据权利要求4所述的桑黄素的提取方法,其特征在于,发酵培养时接种量为10%,发酵温度为28℃,转速为180r/min,通气量为0.6vvm,发酵培养时间为8天。
6.根据权利要求3所述的桑黄素的提取方法,其特征在于,浸膏溶于甲醇后浓度为18-22mg/mL。
7.根据权利要求6所述的桑黄素的提取方法,其特征在于,浸膏溶于甲醇后浓度为20mg/mL。
8.权利要求1所述的桑黄素在制备抗氧化药物方面的应用。
9.权利要求1所述的桑黄素在制备自由基清除剂方面的应用。
10.权利要求1所述的桑黄素在制备抗肿瘤药物或降血糖药物方面的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910647515.3A CN110357843A (zh) | 2019-07-17 | 2019-07-17 | 一种新型桑黄素及其提取方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910647515.3A CN110357843A (zh) | 2019-07-17 | 2019-07-17 | 一种新型桑黄素及其提取方法与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110357843A true CN110357843A (zh) | 2019-10-22 |
Family
ID=68220141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910647515.3A Pending CN110357843A (zh) | 2019-07-17 | 2019-07-17 | 一种新型桑黄素及其提取方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110357843A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111096983A (zh) * | 2020-01-17 | 2020-05-05 | 浙江工业大学 | 具有降血糖活性的桑黄酚类提取物及其制备与应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110095486A (ko) * | 2010-02-19 | 2011-08-25 | 전북대학교산학협력단 | 바우미 상황버섯 유래의 폴리페놀 추출물을 유효성분으로 함유하는 고지혈, 지방간 또는 비만 예방 및 치료용 조성물 |
CN104988192A (zh) * | 2015-06-01 | 2015-10-21 | 宁夏医科大学 | 一种桑黄素d的制备方法 |
-
2019
- 2019-07-17 CN CN201910647515.3A patent/CN110357843A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110095486A (ko) * | 2010-02-19 | 2011-08-25 | 전북대학교산학협력단 | 바우미 상황버섯 유래의 폴리페놀 추출물을 유효성분으로 함유하는 고지혈, 지방간 또는 비만 예방 및 치료용 조성물 |
CN104988192A (zh) * | 2015-06-01 | 2015-10-21 | 宁夏医科大学 | 一种桑黄素d的制备方法 |
Non-Patent Citations (3)
Title |
---|
刘奥: "桑黄(Inonotus baumii)发酵与桑黄素LA分离耦合工艺研究", 《中国优秀硕士学位论文全文数据库,工程科技I辑,B018-83》 * |
刘奥: "桑黄(Inonotus baumii)发酵与桑黄素LA分离耦合工艺研究", 《中国优秀硕士学位论文全文数据库,工程科技I辑,B018-83》, 15 July 2019 (2019-07-15), pages 15 - 35 * |
张慧莹 等: "桑黄素的研究进展", 《中国林副特产》, 30 April 2016 (2016-04-30) * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111096983A (zh) * | 2020-01-17 | 2020-05-05 | 浙江工业大学 | 具有降血糖活性的桑黄酚类提取物及其制备与应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103919712B (zh) | 北虫草提取物及其制备方法和应用 | |
CN103767975B (zh) | 桂花苯乙醇苷提取物在制备美白化妆品中的应用 | |
CN109970538A (zh) | 一类海洋真菌来源的二倍半萜类化合物及其制备方法和在制备抗炎药物中的应用 | |
CN110433114B (zh) | 抑制酪氨酸酶活性的植物提取物及其应用 | |
CN111704544A (zh) | 一种半日花烷型二萜类化合物及其分离方法和应用 | |
CN110357843A (zh) | 一种新型桑黄素及其提取方法与应用 | |
CN109096232B (zh) | 一种联苄基二聚体类化合物及其从金钗石斛中提取分离的方法与应用 | |
CN100372834C (zh) | 一种从小球藻细胞中提取叶黄素的方法 | |
CN113912482A (zh) | 愈创木烷型倍半萜类化合物及其制备和应用 | |
CN101463022B (zh) | 一种中药玉郎伞查耳酮类单体的制备及其应用 | |
CN110343045A (zh) | 芳基四氢萘型木脂素类化合物及制备和应用 | |
CN108929296A (zh) | 一种抗炎苯丙素类化合物及其提取方法与应用 | |
CN110305014A (zh) | 环新木脂烷型木脂素对映异构体及其制备和应用 | |
CN109776561A (zh) | 化合物cytorhizins B和C及其制备方法和在制备抗肿瘤药物中的应用 | |
CN113004299B (zh) | 山竹皮中具有降低餐后血糖的呫吨酮类化合物及其提取方法和应用 | |
CN115851454A (zh) | 嗜氮酮类化合物及其制备方法和在制备神经保护药物中的应用 | |
CN109134488A (zh) | 一种新化合物及其制备方法和在化妆品中的应用 | |
CN106279092B (zh) | 一种双对苯醌类化合物及其提取方法 | |
CN107501072A (zh) | 化合物colletotriconeA及其制备方法和在制备抗肿瘤药物中的应用 | |
CN110204589B (zh) | 青葙子有效成分、提取方法及其在制备神经保护药物方面的应用 | |
CN107028842B (zh) | 玫瑰花渣活性部位萃取方法及其应用 | |
CN104478687B (zh) | 从五味子中提取分离的化合物及其方法和应用 | |
CN103087923A (zh) | 一株球毛壳菌及其代谢产物黄柄曲菌素的制备和应用 | |
CN108299274B (zh) | 一种天然吲哚,其制备方法及应用 | |
CN102250161B (zh) | 具有酪氨酸酶抑制活性的紫罗兰酮类衍生物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191022 |
|
RJ01 | Rejection of invention patent application after publication |